Drugs / GSK369796
GSK369796
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00675064 | May → Oct 2008 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK369796 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00675064 ↗ |
| Known as | BDBM50134936 | ChEMBL registry synonym — accepted as the source's own label CHEMBL147806 ↗ |
| Known as | CHEMBL147806 | ChEMBL registry synonym — accepted as the source's own label CHEMBL147806 ↗ |
| Known as | N-tert-butyl isoquine | ChEMBL registry synonym — accepted as the source's own label CHEMBL147806 ↗ |
| Known as | Ntbisq | ChEMBL registry synonym — accepted as the source's own label CHEMBL147806 ↗ |
| Known as | ZINC1912685 | ChEMBL registry synonym — accepted as the source's own label CHEMBL147806 ↗ |
| Modality | Small molecule | — CHEMBL147806 ↗ |
| Route | Oral | “GSK3697969 orally” NCT00675064 ↗ |